← All trials
NCT04819438
Phase 1Interventional
Includes initial studies to determine the metabolism and pharmacologic actions of drugs in humans, the side effects associated with increasing doses, and to gain early evidence of effectiveness; may include healthy participants and/or patients.
View on ClinicalTrials.gov ↗Timeline
- Start date
- Jan 15, 2021
- Primary completion
- Mar 14, 2021
- Completion date
- Mar 14, 2021
- First posted
- Mar 29, 2021
- Last posted
- Sep 17, 2021
- Enrollment
- 54
- Arms / groups
- 2 / —
- Source
- AACT · ingestion pipeline
Sponsors
- Cross Research S.A.Lead sponsor
- ZambonCollaborator
- Cross Research S.A.Overall official - principal investigator
- Cross Research S.A.Reponsible party - principal investigator
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.